In this advisory video, Stacy L. Chin warns biotech founders that the funding environment has dramatically changed from 2025 to 2026. Investors have pulled back, company valuations have fallen, and governmental shutdowns have further constrained capital. As a result, private funding pipelines for small biotech teams have largely dried up, creating a challenging landscape that founders must navigate.
If you're a biotech founder, especially right now, you need to hear this because the way your startup was funded in 2025 might be very different than 2026 and ahead. So yeah, let's be real. This was a difficult year. And like we said, investors pulled back, valuations dropped, governmental shutdowns. And so a lot of private capital and small teams in this sector nearly vanished in the pipeline or just dried up.
Applying for NIH SBIR in Jan 5, 2027? You Should Be Starting NOW. Here's why...
How to Get Invited to Apply for $305K in NSF SBIR Funding || Step-by-Step Guide
